IGM Biosciences (IGMS) Competitors $1.33 -0.02 (-1.48%) Closing price 04:00 PM EasternExtended Trading$1.34 +0.01 (+0.75%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IGMS vs. AVTE, AVIR, DBVT, ANNX, OLMA, RCKT, CMPS, AARD, ABEO, and GLUEShould you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include Aerovate Therapeutics (AVTE), Atea Pharmaceuticals (AVIR), DBV Technologies (DBVT), Annexon (ANNX), Olema Pharmaceuticals (OLMA), Rocket Pharmaceuticals (RCKT), COMPASS Pathways (CMPS), Aardvark Therapeutics (AARD), Abeona Therapeutics (ABEO), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. IGM Biosciences vs. Its Competitors Aerovate Therapeutics Atea Pharmaceuticals DBV Technologies Annexon Olema Pharmaceuticals Rocket Pharmaceuticals COMPASS Pathways Aardvark Therapeutics Abeona Therapeutics Monte Rosa Therapeutics IGM Biosciences (NASDAQ:IGMS) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership. Does the media refer more to IGMS or AVTE? In the previous week, IGM Biosciences had 4 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 4 mentions for IGM Biosciences and 0 mentions for Aerovate Therapeutics. IGM Biosciences' average media sentiment score of 0.51 beat Aerovate Therapeutics' score of 0.00 indicating that IGM Biosciences is being referred to more favorably in the media. Company Overall Sentiment IGM Biosciences Positive Aerovate Therapeutics Neutral Do analysts prefer IGMS or AVTE? IGM Biosciences currently has a consensus target price of $5.50, indicating a potential upside of 313.53%. Given IGM Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe IGM Biosciences is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IGM Biosciences 1 Sell rating(s) 9 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.90Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is IGMS or AVTE more profitable? Aerovate Therapeutics has a net margin of 0.00% compared to IGM Biosciences' net margin of -7,417.79%. Aerovate Therapeutics' return on equity of -90.19% beat IGM Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets IGM Biosciences-7,417.79% -317.97% -71.43% Aerovate Therapeutics N/A -90.19%-77.47% Do insiders and institutionals have more ownership in IGMS or AVTE? 42.8% of IGM Biosciences shares are owned by institutional investors. 57.0% of IGM Biosciences shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, IGMS or AVTE? IGM Biosciences has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Which has stronger valuation and earnings, IGMS or AVTE? Aerovate Therapeutics has lower revenue, but higher earnings than IGM Biosciences. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIGM Biosciences$2.68M29.67-$195.79M-$3.27-0.41Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-6.15 SummaryIGM Biosciences beats Aerovate Therapeutics on 9 of the 14 factors compared between the two stocks. Get IGM Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IGMS vs. The Competition Export to ExcelMetricIGM BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$80.70M$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E Ratio-0.417.5719.7120.50Price / Sales29.67286.98435.75120.29Price / CashN/A41.1936.8257.86Price / Book1.627.487.985.56Net Income-$195.79M-$55.04M$3.16B$248.40M7 Day Performance3.10%5.44%3.69%6.04%1 Month Performance0.76%2.38%2.91%7.69%1 Year Performance-80.15%5.53%34.30%20.97% IGM Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IGMSIGM Biosciences4.3971 of 5 stars$1.33-1.5%$5.50+313.5%-78.5%$80.70M$2.68M-0.41190AVTEAerovate TherapeuticsN/A$11.14+3.1%N/A-80.2%$322.89MN/A-3.7320High Trading VolumeAVIRAtea Pharmaceuticals2.3212 of 5 stars$3.64-2.7%$6.00+64.8%+12.0%$320.07MN/A-2.2170DBVTDBV Technologies3.7165 of 5 stars$11.01-5.1%$14.75+34.0%+162.5%$317.72M$4.15M-2.2480Analyst UpgradeANNXAnnexon2.6642 of 5 stars$2.73-5.5%$12.50+357.9%-39.2%$317.08MN/A-2.3160Positive NewsOLMAOlema Pharmaceuticals1.7308 of 5 stars$4.45-2.6%$24.50+450.6%-58.3%$312.68MN/A-2.2170Positive NewsRCKTRocket Pharmaceuticals4.8505 of 5 stars$2.81-3.1%$18.60+561.9%-85.9%$309.68MN/A-1.07240Trending NewsCMPSCOMPASS Pathways2.2028 of 5 stars$3.31+1.5%$17.00+413.6%-46.6%$305.01MN/A-1.66120AARDAardvark TherapeuticsN/A$13.92flat$33.00+137.1%N/A$302.01MN/A0.0018ABEOAbeona Therapeutics3.986 of 5 stars$5.75-2.4%$19.25+234.8%+26.7%$301.31M$3.50M-4.5390GLUEMonte Rosa Therapeutics1.3398 of 5 stars$4.97+2.1%$15.33+208.5%+36.5%$299.55M$75.62M62.1390Positive News Related Companies and Tools Related Companies AVTE Alternatives AVIR Alternatives DBVT Alternatives ANNX Alternatives OLMA Alternatives RCKT Alternatives CMPS Alternatives AARD Alternatives ABEO Alternatives GLUE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IGMS) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored$3,200 from your phone?No charts. No crypto. No stock picking. With just a regular brokerage app and Jeff Clark’s “Crossfire” meth...TradeSmith | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGM Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IGMS Stock Alerts